Navigation Links
Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
Date:10/24/2008

signed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

For further information please contact:

Novexel

Gordon Waldron, CFO

Tel: +33-1-5714-0777

gordon.waldron@novexel.com

Citigate Dewe Rogerson

Amber Bielecka/David Dible/Nina Enegren

Tel.: +44(0)207-638-95-71

amber.bielecka@citigatedr.co.uk


'/>"/>
SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
3. Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora
4. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
5. Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
6. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
7. Cytopia Scientific Presentations on JAK2 Inhibitor Program
8. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
10. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
11. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)... Dec. 17, 2014  Strategic Health Services, Inc. (SHS), ... today announced a strategic agreement with QualCare, Inc., a leading ... Jersey regional marketplace.  This agreement will further ... and wellness solutions QualCare brings to its clients in ... region. QualCare plans cover more than ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... PHILADELPHIA and LONDON , June 28 ... portfolio of drugs, whilst the proportion of total sales from newer drugs ... Factbook complied by CMR International, a Thomson Reuters business. , ... The new edition of the R&D Factbook ...
... Fla. , June 26 Data ... that linagliptin achieved statistically significant and sustained reductions ... (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose ... dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral ...
Cached Medicine Technology:Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 2Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 2Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 4Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 5Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 6Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 7Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 8
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... TX (PRWEB) December 15, 2014 Emergo ... offices in 26 countries in North and South America, ... accepting responses from industry participants for its 2015 Medical ... in order to identify upcoming business and market trends ... respondents. , The survey targets areas including:, ...
(Date:12/15/2014)... CA (PRWEB) December 15, 2014 At ... the organizations AutismOne and Focus Autism ... enlighten attendees with research on the effects of toxins ... testing and intervention information. , Luminaries such as ... researchers from abroad with esteemed, credentialed colleagues of the ...
(Date:12/15/2014)... IL (PRWEB) December 15, 2014 Kenmode ... joined the firm as Director of Quality Assurance. ... managing quality systems, processes and certifications for manufacturers in ... the posts of Corporate Quality Manager at Sonoco Products ... Quality at NetCom, Inc., and Quality Assurance Manager for ...
(Date:12/15/2014)... 2014 Metal drilling machines ... 5. This score indicates that neither buyers nor suppliers ... “Suppliers have been raising the price of metal drilling ... to rising demand,” according to IBISWorld business research analyst, ... , During the past three years, high price driver ...
Breaking Medicine News(10 mins):Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Metal Drilling Machines Procurement Category Market Research Report Now Available from IBISWorld 3
... Reporter , THURSDAY, May 19 (HealthDay News) -- The U.S. ... drug Avandia will no longer be sold at retail pharmacies ... to patients. According to the new rules, which will ... be available to patients who,ve been safely using the ...
... University of Louisville, UCLA and the California Institute of Technology ... a paralyzed male volunteer at Louisville,s Frazier Rehab Institute. It ... potential clinical therapies for paralysis. The study is ... The man, Rob Summers, age 25, was completely ...
... (HealthDay News) -- When people need a self-esteem boost, they ... when they make those expensive purchases, according to new research. ... and then some of the participants were told that they ... while others were told they did well on the test. ...
... (HealthDay News) -- The human ability to stand on two legs ... new study suggests. University of Utah researchers used a punching ... by male boxers and martial arts experts as they hit the ... men struck the bag from a standing position and while on ...
... with defects in mismatch repair--one of the body,s systems ... survival rates than patients without such defects, according to ... Journal of the National Cancer Institute. About ... defects. Some defects are caused by the inherited gene ...
... 2011 The Children,s Health Insurance Program Reauthorization Act ... care quality measures to be identified for voluntary use ... (CHIP), which together cover almost 40 million American children ... the official journal of the American Pediatric Association, noted ...
Cached Medicine News:Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 2Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 3Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 2Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 3Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 4Health News:Buying Luxury Items on Credit May Be Ego Booster 2Health News:Punches Land Harder When Delivered From Above: Study 2Health News:DNA repair system affects colon cancer recurrence and survival 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 3Health News:Important info about CHIPRA core set of recommended health care quality measures released 4Health News:Important info about CHIPRA core set of recommended health care quality measures released 5
Unipolar Atrial "J" Lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: